TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
about
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentThe Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaAnalysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.Minimal Residual Disease Eradication in CML: Does It Really Matter?Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
P2860
Q30242015-75F50CDD-9A17-4CC9-97AB-19A20D4D0054Q33815980-90CDFE17-3A67-4405-9F13-EC2977413904Q36229161-4371F9BC-4C6A-4A82-B3F8-899D64354BF0Q36237990-CF9C0A97-41CC-49E8-9A7B-46A3E2F9C23DQ36288815-04B47741-7C03-4EF0-9302-5A5779D95BB8Q36547224-1658581C-E440-453A-B8ED-DCF25BC80146Q36734508-32117564-AD4B-4234-825A-3C3C4E7248E8Q36833021-C0BDA25F-527F-4496-A58C-9E8328771363Q38602633-1D6744D3-358E-4D43-BDB8-DC59070D087AQ38685803-BF0A37D0-59C5-4F28-A15A-ADE50C05BCDDQ38748512-67D50318-1D6B-4812-9064-A7DC0346D16CQ38797683-3CF36137-701D-4890-979C-7D01924CE20CQ39457369-4052018C-CE4D-4604-90E0-DEF752A593E6Q47096076-6C3B27CF-310B-426B-A739-B3603C9CEB3DQ47211218-38D102EB-74ED-434A-AC1F-230ADEFA2B87Q47216949-420BCB40-DA29-4513-BC97-7ADB98D257E8Q50784710-B7839701-4BF8-4B64-A439-E6647F3E2C82Q50911365-90671C05-C0A8-46AF-8E66-45AD0649392AQ50997822-4DC551B1-2E7C-42D8-BF44-3A7864EDC24CQ52715772-E90F9098-E59A-49CC-8964-39D0B76CEB9AQ53206022-45931498-B16B-48EE-ADAD-4658C58E6D0DQ57069646-EA58DA1B-BCC6-498B-B6DD-43082E85FD06
P2860
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TIDEL-II: first-line use of im ...... me-dependent molecular targets
@en
TIDEL-II: first-line use of im ...... e-dependent molecular targets.
@nl
type
label
TIDEL-II: first-line use of im ...... me-dependent molecular targets
@en
TIDEL-II: first-line use of im ...... e-dependent molecular targets.
@nl
prefLabel
TIDEL-II: first-line use of im ...... me-dependent molecular targets
@en
TIDEL-II: first-line use of im ...... e-dependent molecular targets.
@nl
P2093
P2860
P50
P1433
P1476
TIDEL-II: first-line use of im ...... me-dependent molecular targets
@en
P2093
Alan Herschtal
Andrew P Grigg
Anthony K Mills
Anthony P Schwarer
Australasian Leukaemia and Lymphoma Group
Cecily J Forsyth
Christopher K Arthur
David T Yeung
Devendra K Hiwase
Jennifer Beresford
P2860
P304
P356
10.1182/BLOOD-2014-07-590315
P407
P577
2014-12-17T00:00:00Z